Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

New Indication Alert: Dupixent® Approval for EoE Extended to Patients Over 1 Year Old in Canada

Sep 12, 2024

On 12 September 2024, Sanofi and Regeneron announced that Health Canada has approved Dupixent® (dupilumab) for the treatment of patients aged 1 year and older, weighing at least 15 kg, with eosinophilic esophagitis (EoE).  This approval expands the initial Health Canada approval for EoE in May 2023 for patients aged 12 years and older, weighing at least 40 kg.

Dupixent® has previously received FDA approval for these indications, being approved for paediatric patients aged 1 to 11 years (weighing at least 15 kg) with EOE in January 2024 and for EoE in patients 12 years and older in May 2022.